Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Determinants of the changes in glycemic control with exercise training in type 2 diabetes: a randomized trial
Johannsen NM, Sparks LM, Zhang Z, Earnest CP, Smith SR, Church TS, Ravussin E
PLoS ONE 2013 Jun;8(6):e62973
clinical trial
4/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: No; Intention-to-treat analysis: No; Between-group comparisons: No; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

AIMS: To assess the determinants of exercise training-induced improvements in glucose control (HbA1C) including changes in serum total adiponectin and FFA concentrations, and skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) protein content. METHODS: A sub-cohort (n = 35; 48% men; 74% caucasian) from the HART-D study undertaking muscle biopsies before and after 9 months of aerobic (AT), resistance (RT), or combination training (ATRT). RESULTS: Changes in HbA1C were associated with changes in adiponectin (r = -0.45, p = 0.007). Participants diagnosed with type 2 diabetes for a longer duration had the largest increase in PGC-1alpha (r = 0.44, p = 0.008). Statistical modeling examining changes in HbA1C suggested that male sex (p = 0.05), non-Caucasian ethnicity (p = 0.02), duration of type 2 diabetes (r = 0.40; p < 0.002) and changes in FFA (r = 0.36; p < 0.004), adiponectin (r = -0.26; p < 0.03), and PGC-1alpha (r = -0.28; p = 0.02) explain about 65% of the variability in the changes in HbA1C. CONCLUSIONS: Decreases in HbA1C after 9 months of exercise were associated with shorter duration of diabetes, lowering of serum FFA concentrations, increasing serum adiponectin concentrations and increasing skeletal muscle PGC-1alpha protein expression. TRIAL REGISTRATION: ClinicalTrials.gov NCT00458133.

Full text (sometimes free) may be available at these link(s):      help